Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Weill Medical College of Cornell University
To determine the clinical activity of 177Lu -J591 for the treatment of patients with metastatic, androgen-independent prostate cancer.
Patients will receive a single dose of J591 (total antibody of 20 mg) consisting of antibody chelated with 177Lu at a dose of 65 or 70 mCi/m2 with a specific activity of 12-15 mCi/mg plus non-radiolabeled antibody.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologic diagnosis of prostate adenocarcinoma.
Metastatic prostate cancer progressive on imaging studies and/or rising PSA despite adequate medical or surgical castration therapy.
Progressed following discontinuation of anti-androgen therapy, if received.
Serum testosterone \< 50 ng/ml
You may not be if
Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of treatment.
Use of PC-SPES within 4 weeks of treatment.
Use of red blood cell or platelet transfusions within 4 weeks of treatment.
Use of hematopoietic growth factors within 4 weeks of treatment.
Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.
Bone scan demonstrating confluent lesions involving both axial and appendicular skeleton.
Prior radiation therapy encompassing \>25% of skeleton.
Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®).
Active angina pectoris or NY Heart Association Class III-IV.
History of deep vein thrombophlebitis and/or pulmonary embolus within 3 months of study entry.
Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
Prior monoclonal antibody therapy with the exception of ProstaScint®
Prior investigational therapy (medications or devices) within 6 weeks of treatment.
